2007
DOI: 10.1111/j.1524-475x.2007.00307.x
|View full text |Cite
|
Sign up to set email alerts
|

Randomized, multicenter, double‐blind, and placebo‐controlled trial using topical recombinant human acidic fibroblast growth factor for deep partial‐thickness burns and skin graft donor site

Abstract: Wound healing is a dynamic and complex biologic process that could be accelerated by growth factors. To investigate the efficacy of topical recombinant human acidic fibroblast growth factor (rh-aFGF) treatment in deep partial-thickness burn or skin graft donor sites, we designed a randomized, multicenter, double-blind, and placebo-controlled clinical trial. The healing rate, fully healed rate, and healing time were evaluated to assess the efficacy of rh-aFGF application. Laboratory examinations and abnormal si… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
21
0

Year Published

2012
2012
2023
2023

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 63 publications
(23 citation statements)
references
References 15 publications
1
21
0
Order By: Relevance
“…The insulin liposomal formulation was added to chitosan gel that has a wound‐healing activity. Our results were in accordance with several previous reports that have proven the efficacy of topical insulin in accelerating the healing process of skin burns, acute and chronic wounds, and diabetic foot and pressure ulcers…”
Section: Discussionsupporting
confidence: 93%
See 1 more Smart Citation
“…The insulin liposomal formulation was added to chitosan gel that has a wound‐healing activity. Our results were in accordance with several previous reports that have proven the efficacy of topical insulin in accelerating the healing process of skin burns, acute and chronic wounds, and diabetic foot and pressure ulcers…”
Section: Discussionsupporting
confidence: 93%
“…were 45 (43-47.8) and 48 (41-50) for test and placebo groups, respectively, with a non-significant difference (P = .576). After 6 days, values were 13 (11)(12)(13)(14) and 21 (20)(21)(22)(23)(24)(25)(26)(27)(28) for test and placebo groups, respectively. The test group showed a statistically significantly lower median score than placebo (P < .001) ( Table 2).…”
Section: The Median and Iqr Values For Ohip-14 Scores At Base Linementioning
confidence: 99%
“…22,23 In animal models of delayed wound healing (diabetic and aged animals), abnormal expression of FGF-1, FGF-2, and FGF-7 and diminished expression of FGFRs have been reported, and exogenous FGFs have been successfully used to improve tissue repair. 24,25 These observations led to development of a number of clinical trials. Fibroblast growth factors 1 and 2 have been used for treatment of chronic wounds and burns, with only modest improvements in healing rates being observed.…”
Section: Fibroblast Growth Factormentioning
confidence: 99%
“…Administration of FGFs successfully improved wound healing in these animals [85]. In this regard, Tsuboi and Rifkin [86] reported that bFGF (FGF-2) accelerated wound healing in a diabetic mouse model.…”
Section: Regenerative Therapies For Skin Wound Managementmentioning
confidence: 99%
“…Based on the aforementioned promising animal models, clinical trials in humans were performed where FGF-1 and -2 were used for treating chronic (burn) wounds and resulted in a modest improvement in the healing rates in some studies [81,88]. In another study by Ma et al [89], the use of human recombinant FGF-1 resulted in accelerated healing of deep partial-thickness burn wounds. Future studies may provide better insights on the beneficial effects of different types of FGFs in different patient groups.…”
Section: Regenerative Therapies For Skin Wound Managementmentioning
confidence: 99%